ArticleBiological psychiatry2026
Intermittent Ketamine and Neuromodulation Treatment Evoke Synergistic Antidepressant-Relevant Action.
Article in Biological psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundHistorically, the most effective antidepressant is electroconvulsive therapy (ECT). ECT induces cognitive side effects and commonly requires numerous treatments over several weeks for robust symptom relief. The rapid response that can be observed following ketamine treatment has led to a reconceptualization of how pharmacotherapy can treat depression. One subanesthetic infusion can alleviate symptoms within hours; however, sustained relief also requires multiple doses. Clinical studies have combined ECT and ketamine to improve therapeutic outcomes but have yielded mixed results.
methodsWe used behavioral pharmacology and ex vivo hippocampal slice electrophysiology to test the hypothesis that a preclinical ECT model, electroconvulsive stimulation (ECS), and ketamine can exert synergistic antidepressant-relevant effects in adult mice dependent on dose and dose interval.
resultsRepeated doses of ketamine, but not ECS, led to a metaplasticity characterized by an increased magnitude of synaptic potentiation at the hippocampal Schaffer collateral-CA1 synapse. Targeting ketamine-induced metaplasticity intermittently (i.e., 24-hour interval) by delivering individual, subeffective ketamine and ECS doses produced synergistic antidepressant-like synaptic and behavioral outcomes that resembled the actions of an effective ketamine dose. Unlike repeated ECS, intermittent ketamine and ECS administration yielded antidepressant-relevant synaptic and behavioral actions without impairing cognition. Antidepressant-like effects produced by ketamine alone were prolonged when intermittently administered with an individual ECS treatment. Synergistic effects were precluded when ketamine and ECS were delivered concurrently.
conclusionsKetamine and ECS exhibited time-sensitive, synergistic antidepressant-like actions, suggesting that strategies targeting metaplasticity at glutamatergic synapses can be used to reduce side effects while augmenting, accelerating, and prolonging antidepressant outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.